Nicole Prinz

Dr. Nicole Prinz


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Diabetes Care
Verified
Journal Article
Open access
PDF file
BKBeate Karges
Beate Karges
NPNicole Prinz
Nicole Prinz
KPKerstin Placzek
Kerstin Placzek
NDNicolin Datz
Nicolin Datz
MPMatthias Papsch
Matthias Papsch
RHReinhard W. Holl
Reinhard W. Holl
OBJECTIVE: To investigate natural course, treatment, and outcomes in familial versus sporadic type 1 diabetes. RESEARCH DESIGN AND METHODS: In a population-based study, we compared patients with onset of type 1 diabetes before the age of 20 years who had a first-degree relative with type 1 diabetes (familial diabetes) with patients with type 1 diabetes who had no first-degree relative with type 1 diabetes (sporadic diabetes) at diagnosis and over the first 10 treatment years, using multivariable regression and proportional hazards models. Patients were identified from the Diabetes Prospective Follow-up Registry (DPV) between 1995 and 2018. RESULTS: Of 57,371 patients with type 1 diabetes, 53,606 (93.4%) had sporadic diabetes and 3,765 (6.6%) had familial diabetes. Familial diabetes, compared with sporadic diabetes, was associated with younger age (median 7.9 vs. 9.7 years, P < 0.001), lower prevalence of ketoacidosis (11.9% vs. 20.4%, P < 0.001), and lower HbA1c levels (9.7% vs. 11.1%, P < 0.001) at onset and higher prevalence of associated autoimmune disease (16.7% vs. 13.6%, P < 0.001). Over 10 years, patients with familial diabetes, in comparison with sporadic diabetes, more often used insulin pumps (P < 0.001) and had a lower rate of severe hypoglycemia (12.97 vs. 14.44 per 100 patient-years, P < 0.001) but similar HbA1c levels (P ≥ 0.08) and ketoacidosis rates (1.85 vs. 2.06 per 100 patient-years, P = 0.11). In familial and sporadic diabetes, absence of ketoacidosis at onset predicted fewer events of severe hypoglycemia (hazard ratio [HR] 0.67, P < 0.001, and 0.91, P < 0.001, respectively) and of ketoacidosis (HR 0.64, P = 0.007, and 0.66, P < 0.001, respectively) after 10 years. CONCLUSIONS: Familial type 1 diabetes, compared with sporadic type 1 diabetes, is characterized by earlier disease manifestation and higher autoimmune comorbidity as well as less metabolic decompensation at onset, likely related to higher disease awareness in affected families, while the course of disease is similar. These findings may have implications for the generalizability of results of diabetes prevention trials from patients with familial type 1 diabetes to patients with sporadic type 1 diabetes.

9 January 2024 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
Angela GallerAngela Galler
Angela Galler
ATAngelika Thönnes
Angelika Thönnes
JJJens Joas
Jens Joas
CJChristine Joisten
Christine Joisten
AKAntje Körner
Antje Körner
AIApv Initiative
Apv Initiative
Background: Mental disorders are important comorbidities in youth with obesity. Aim was to describe the clinical characteristics and outcome of youth with overweight or obesity having comorbid mental disorders. Methods: Data from children, adolescents, and young adults (age 6–30 years) with overweight or obesity and mental disorders (depression, anxiety disorder, eating disorder, attention deficit disorder (ADHD)) from 226 centers in Germany and Austria participating in the Adiposity Patient Registry (APV) were analyzed and compared with those without reported mental disorders using regression modeling. Results: Mental health comorbidity was reported in a total of 3969 out of 114,248 individuals with overweight or obesity: 42.5% had ADHD, 31.3% anxiety disorders, 24.3% depression, and 12.9% eating disorders. Being male (OR 1.39 (95%CI 1.27;1.52)), of older age (1.42 (1.25;1.62)), or with extreme obesity (1.45 (1.30;1.63)) were most strongly associated with mental health comorbidity. Regression analysis showed that mean BMI-SDS was significantly higher in the group of individuals with depression and eating disorders (BMI-SDS 2.13 (lower; upper mean:2.09;2.16) and 2.22 (2.17;2.26)) compared to those without reported mental health comorbidity (BMI-SDS 2.008 (2.005;2.011); p < 0.001). In youth with ADHD, BMI-SDS was lower compared to those without reported mental disorders (BMI-SDS 1.91 (1.89;1.93) vs 2.008 (2.005;2.011); p < 0.001). Proportion of severe obesity was higher in individuals with depression (23.7%), anxiety disorders (17.8%), and eating disorders (33.3%), but lower in ADHD (10.3%), compared to those without reported mental disorders (13.5%, p < 0.002). Proportions of dyslipidaemia and abnormal carbohydrate metabolism were not different in youth with and without reported mental health comorbidity. BMI-SDS change after one year of lifestyle intervention program ranged between −0.22 and −0.16 and was similar in youth without and with different mental disorders. Conclusion: Health care professionals caring for youth with overweight or obesity should be aware of comorbid mental disorders and regular mental health screening should be considered.

16 August 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
MCMark A. Clements
Mark A. Clements
ASAnke Schwandt
Anke Schwandt
KDKim C. Donaghue
Kim C. Donaghue
KMKellee Miller
Kellee Miller
ULUrsula Lück
Ursula Lück
OIon behalf of the Australasian Diabetes Data Network (ADDN) Study Group, the T1D Exchange Clinic Network (T1DX), and the German/Austrian/Luxembourgian Diabetes‐Patienten‐Verlaufsdokumentation (DPV) initiative
on behalf of the Australasian Diabetes Data Network (ADDN) Study Group, the T1D Exchange Clinic Network (T1DX), and the German/Austrian/Luxembourgian Diabetes‐Patienten‐Verlaufsdokumentation (DPV) initiative

29 October 2015 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
PDF file
NPNicole Prinz
Nicole Prinz
JSJulia Carolin Stingl
Julia Carolin Stingl
ADAlbrecht Dapp
Albrecht Dapp
MDMichael D. Denkinger
Michael D. Denkinger
PFPeter Fasching
Peter Fasching
RHReinhard W. Holl
Reinhard W. Holl

1 April 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
TRThomas Reinehr
Thomas Reinehr
BDBarbara Dieris
Barbara Dieris
Angela GallerAngela Galler
Angela Galler
MTMartin Teufel
Martin Teufel
GBGabriele Berger
Gabriele Berger
NPNicole Prinz
Nicole Prinz

1 January 2016 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
NPNicole Prinz
Nicole Prinz
CBChristina Bächle
Christina Bächle
MBMarianne Becker
Marianne Becker
GBGabriele Berger
Gabriele Berger
AGAngela Galler
Angela Galler
OIOn Behalf Of The Dpv Initiative
On Behalf Of The Dpv Initiative
Background: The latest American Association of Clinical Endocrinologists/American College of Endocrinologists consensus statement published in 2014 does not recommend continuous subcutaneous insulin infusion (CSII) in patients with mental health problems. This study investigated the use and discontinuation of CSII in daily routine care of type 1 diabetes (T1D) patients with or without comorbid mental disorders. Materials and Methods: Insulin-treated T1D patients ( n = 48,700) between 5 and 30 years of age (median [interquartile range], 15.6 [12.0–17.7] years) from the German/Austrian diabetes patient follow-up registry (DPV) were studied. A comorbid diagnosis and/or specific treatment of mental disorder was documented in 3,158 (6.5%) patients: attention-deficit hyperactivity disorder (ADHD), n = 1,352; depression, n = 692; eating disorders, n = 395; needle phobia, n = 319; anxiety/obsessive compulsive disorder (OCD), n = 231; and psychosis and/or neuroleptic medication, n = 169. Multivariable logistic regression with age, sex, diabetes duration, and migration background as independent variables was used to compare groups. Results: After adjustment for confounders, use of CSII was more common in patients with depression (41.5%), anxiety/OCD (41.4%), or needle phobia (75.8%) compared with patients without mental disorders (34.6%) (each P < 0.05). By contrast, psychotic patients (26.2%, P < 0.05) used CSII less often, and patients with ADHD (36.3%) or eating disorders (33.9%) used it with a similar frequency. Compared with patients without mental disorders (5.1%), the rate of CSII discontinuation was higher in patients with ADHD (9.7%), depression (8.2%), or eating disorders (10.0%) ( P < 0.05, respectively) but similar in patients with anxiety/OCD (6.0%), psychosis (4.2%), or needle phobia (5.3%). Conclusions: In routine diabetes care, CSII use and discontinuation vary widely among T1D patients with mental disorders and indicate clear differences from the latest recommendations.